Predicting Progression of Developing Myeloma in a High-Risk Screened Population

NCT ID: NCT05837884

Last Updated: 2025-07-28

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 2000 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-09-05
• Study Completion Date: 2028-06-30

Brief Summary

We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions.

Our overarching hypothesis is that early detection of MGUS/SMM in a high- risk population, along with the comprehensive characterization of genomic/epigenomic and microenvironmental/immune regulators of disease progression will lead to strategies that intercept disease progression and improve survival.

Detailed Description

Multiple Myeloma (MM) is a plasma cell dyscrasia characterized by bone marrow (BM) infiltration and lytic bone lesions. Over 30, 000 Americans are diagnosed annually with MM. The estimated US prevalence is rising, and this trend is likely to continue due to improvements in diagnosis and therapy. Despite recent advances in therapy, MM remains a fatal disease with a median survival of 5-10 years and most patients still succumb to disease progression. Although many patients are diagnosed with earlier phases of disease, most patients do not receive treatment until their disease progresses, at which time they have overt end-organ damage. This concept of initiating therapy at the time of symptomatic disease is analogous to initiating therapy in patients with solid tumors only after the development of measurable metastatic disease. It is therefore not surprising that cure is not achieved for most patients with MM.

Recent studies have shown that MM is consistently preceded by MGUS and SMM. The incidence of MGUS is about 3% of the general population aged 50 years. This was through the analysis of a cohort of 77,000 people enrolled in a prospective population-based cancer screening trial that showed that multiple myeloma is consistently preceded by a precursor MGUS state. MGUS progresses to over MM at a slow rate of 1% per year, but in some patients, the risk may be as high as 58% in 20 years. SMM has an annual risk of progression of 10%. The rate of progression of high-risk SMM is as high as 70% in 5 years.

MGUS and SMM are often diagnosed incidentally when a physician orders a serum protein electrophoresis (SPEP) for a differential diagnosis of anemia, bone pain or renal insufficiency. Screening for early cancer detection has been implemented for many cancers including breast cancer (with mammography) and colon cancer (with colonoscopy) with variable success. However, a simple blood test for SPEP can accurately diagnose the presence of a plasma cell dyscrasia, indicating that early detection can identify these precursor conditions. In addition, recent studies have demonstrated that early detection of MGUS can lead to improved overall survival compared to incidental diagnosis of overt myeloma, presumably because these patients are followed more carefully and receive treatment before end-organ damage develops.

Therefore, high-risk populations include individuals with a first-degree relative that has been diagnosed with a plasma cell dyscrasia or other hematologic malignancy.

Conditions

Healthy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SCREENING
• Blinding Strategy: NONE

Study Groups

First-degree relative of a patient with a plasma cell dyscrasia or another blood cancer.

Individuals will ensure they are eligible by filling out an eligibility questionnaire confirming they meet all eligibility criteria. Individuals will provide informed consent to complete the baseline questionnaire and provide a blood sample that will be used to determine whether they have a monoclonal protein

Group Type: OTHER

blood sampling

Intervention Type: DIAGNOSTIC_TEST

Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein

Interventions

blood sampling

Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Must meet criteria of the high-risk population as described with one of the below criteria

• ≥ 30 years AND
• first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.

OR

• Age ≥ 18 years with 2 or more first- or second-degree relatives with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer '
• Voluntary written informed consent must be given with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care

Exclusion Criteria

• • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy.

• Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia
• Female patient who have a positive serum pregnancy test during the screening period or a positive pregnancy test.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Dana-Farber Cancer Institute

OTHER

Sponsor Role: collaborator

Tel-Aviv Sourasky Medical Center

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

TASMC

Tel Aviv, , Israel

Site Status: RECRUITING

Countries

Israel

Central Contacts

Irit Avivi, Prf

Role: CONTACT

iritavi@tlvmc.gov.il

-97236973782

Ella Krayzler

Role: CONTACT

ellakr@tlvmc.gov.il

-97236947231

Facility Contacts

Irit Avivi, MD

Role: primary

Other Identifiers

PROMISE-ISRAEL

Identifier Type: -

Identifier Source: org_study_id